This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Axonics, Inc.
Axonics, Inc., a leading innovator in the medical device industry, is headquartered in the United States. Founded in 2013, the company has rapidly established itself as a key player in the development of advanced neuromodulation therapies, particularly for bladder and bowel control. Axonics is renowned for its unique sacral neuromodulation systems, which offer patients a minimally invasive solution for managing overactive bladder and faecal incontinence. The company’s flagship product, the Axonics Sacral Neuromodulation System, stands out for its rechargeable technology, providing longer-lasting performance compared to traditional devices. With a strong market position and a commitment to improving patient outcomes, Axonics has achieved significant milestones, including FDA approvals and expanding its operational reach across North America and Europe. The company continues to drive innovation in the field, enhancing the quality of life for countless individuals.
DitchCarbon Score
How does Axonics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Axonics, Inc.'s score of 90 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Axonics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures. The company is a current subsidiary of Boston Scientific Corporation, which may influence its climate commitments and emissions reporting. While Axonics has not set its own reduction targets, it inherits climate initiatives from Boston Scientific Corporation. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions in line with climate science. The specific targets and achievements of these initiatives are cascaded from Boston Scientific, reflecting a commitment to sustainability and climate action at the corporate level. As part of its broader corporate family, Axonics aligns with industry standards for climate commitments, although detailed metrics on emissions reductions or specific targets have not been disclosed. The company is expected to adhere to the sustainability practices and goals set forth by its parent organisation, Boston Scientific Corporation, which is actively engaged in reducing its carbon footprint and enhancing environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Axonics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
